The classical cycle of investigation, hypothesis and experimentation in clinical research
2.2 What Is Research in Medical and Dental Schools?
What is reseach in medical and dental schools?
A Philosophy of investigation |
|
---|---|
Clinical |
Detached analysis of response to therapies, outcomes of treatments, analysis of patients, epidemiology, etc. |
Applied |
Disease groups, classification. Clinical trials, investigation using patients |
Basic |
Hypothesis-based investigation but not necessarily with obvious clinical benefit |

Clinical research in oral mucosal diseases
2.3 Multidisciplinary Clinics
Multidisciplinary clinics can allow the collection of large numbers of patients with similar clinical diseases and make much more efficient the journey from applied research to changes in clinical practice. At Guy’s Hospital Dental School (now King’s College London Dental Institute), multidisciplinary clinics were established in the 1990s for (a) Sjögren’s syndrome with the Departments of Rheumatology, Ophthalmology and Immunology; (b) orofacial granulomatosis with the Departments of Gastroenterology, Immunology and Nutrition; (c) bullous diseases with the Departments of Dermatology and with Moorfields Eye Hospital, Ophthalmology; and (d) Behcet’s syndrome with the Department of Ophthalmology and Rheumatology. These multidisciplinary clinics have led to the Dental School being host to regional centres in each of these conditions and have led to changes in the management of several due to research, application of findings and assessment of clinical outcomes. It can be argued that without a robust system of disease severity measures and of measurement of clinical outcomes to management, any research leading to clinical application is unlikely to fulfil its full potential.
2.4 Assessment of Disease Severity and Treatment Responses in Oral Mucosal Disease
It is a sad truism and reflection on the field that few oral medicine treatments are evidence-based, even those regarded as standard therapies. Until the last few years, there had been a lack of any method to routinely assess disease severity and thus of quantifying responses to therapies. This led to the obvious need to devise and validate oral disease severity scores for a variety of conditions seen in routine clinical practice which could also be used for assessing treatment responses.
The benefits of a scoring system for mucosal disease severity are that (a) they can indicate the severity of disease, (b) they are needed to indicate the efficacy of any treatments, (c) they may distinguish between or reveal between disease subgroups, (d) they may assist in deciding to implement or withhold treatment and (e) they are a routine clinical audit tool which can also be used for research.
Any such oral disease severity scoring systems (ODSS) must be objective and must be reproducible; they should be easy to use and they should be widely applicable. Fortunately such ODSS have been created and validated and are used for recurrent aphthous ulceration [1], lichen planus [2], pemphigus [3], mucous membrane pemphigoid [4], orofacial granulomatosis [5] and dry mouth assessment [6].
2.5 Bullous Diseases

Clinical examples of (a) MMP involving the upper right gingivae and (b) pemphigus vulgaris in the healing phase in the right buccal mucosa
Such richness in clinical material carries with it an obligation to perform basic research, which might lead to identification of clinical phenotypes and improvement in patient management. Greater than 20 peer-reviewed research papers have emanated from this clinic along with Master students in Oral Medicine and five higher degrees (MD/PhDs).

An oral disease severity scoring system for mucous membrane pemphigoid. Seventeen intraoral sites are each scored for the presence of disease severity between 1–3, to give a total for the patient at each visit (plus a pain score) (see [3])
This multidisciplinary research clinically was supported by laboratory-based investigations in immunology, immunopathology and ophthalmology. This has led to the definition of the clinical spectrum, identification of disease subgroups, the study of isotype specificity and of the role of IgA antibodies in disease severity, HLA associations and antigen specificity. The recognition that a B-cell- and antibody-mediated disease is driven by T-cell responses to antigens and epitopes has also been studied [11].
• Laboratory studies with immunology, immunopathology |
– Target antigens in MMP in relation to clinical phenotype: BP180, a6b4, NC16a, laminin 5 |
– Antibody isotypes: IgG, IgA, secretory IgA |
– Use of saliva as diagnostic fluid |
• Clinical studies with dermatology |
– Distinct clinical phenotypes of oral MMP |
– Oral disease severity scoring |
– Different clinical phenotypes may respond to different therapies |
• Three main clinical oral phenotypes of MMP |
• Two main immunofluorescent types relating to target antigens (BP180 and a6b4, laminin 5) |
• Serum IgG antibody titre correlates with disease severity |
• Serum IgG and IgA antibodies combined lead to a more severe disease |
• Different clinical phenotypes respond to different drugs |
• Salivary IgA and IgG antibodies to BP180-NC16a are diagnostic biomarkers in mucous membrane pemphigoid |
• The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels |
• The transition of pemphigus vulgaris into pemphigus foliaceus related to Dsg antibodies |
• Oral and genital lichenoid reactions associated with circulating autoantibodies to desmoplakins I and II |
• Serum and salivary IgG and IgA antibodies to Dsg3 in mucosal pemphigus vulgaris |
2.6 Orofacial Granulomatosis


Stay updated, free dental videos. Join our Telegram channel

VIDEdental - Online dental courses

